BC
RPTX

Bartlett & Co’s Repare Therapeutics RPTX Stock Holding History

Bartlett & Co’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,000
Closed -$21K – 1172
2023
Q2 		$21K Hold
2,000
– – ﹤0.01% 817
2023
Q1 		$20K Hold
2,000
– – ﹤0.01% 713
2022
Q4 		$29K Hold
2,000
– – ﹤0.01% 660
2022
Q3 		$24K Hold
2,000
– – ﹤0.01% 676
2022
Q2 		$28K Buy
+2,000
New +$23.6K ﹤0.01% 677

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bartlett & Co's RPTX Position: Q3 2023 in Review

Bartlett & Co sold out of Repare Therapeutics (RPTX) in Q3 2023, closing a stake of 2,000 shares — an estimated $21K sold.

Bartlett & Co first reported a position in RPTX in Q2 2022 and held it in 5 quarters. The position peaked at $29K in Q4 2022. 76 funds tracked by Wall St. Rank hold RPTX as of Q3 2023.

  • Bartlett & Co reported no remaining Repare Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Bartlett & Co sold 2,000 Repare Therapeutics shares in Q3 2023, an estimated $21K.
  • Bartlett & Co first reported a position in Repare Therapeutics in Q2 2022 and held it in 5 quarters.
  • Bartlett & Co's Repare Therapeutics position peaked at $29K in Q4 2022.
  • 76 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2023.

Based on Bartlett & Co's 13F filing for Q3 2023, filed 10 Oct 2023.